Skip to main content
. 2019 Dec 5;3(23):3953–3961. doi: 10.1182/bloodadvances.2019000989

Table 3.

Multivariate analyses

Cohorts and variables PFS, HR (95% CI) OS, HR (95% CI)
Entire cohort n = 79 n = 109
 Age (>60 y vs ≤60 y) Not included 1.49 (0.93-2.40), P = .099
 Performance status (2-4 vs 0-1) Not included 1.17 (0.67-2.06), P = .587
 LDH (elevated vs normal) 1.61 (0.96-2.70), P = .071 Not included
 Treatment (HDMTX vs others) 0.69 (0.43-1.11), P = .125 0.30 (0.19-0.46), P < .001
 BCL6 FISH (positive vs negative) 2.06 (1.22-3.49), P = .007 1.55 (0.98-2.46), P = .064
HDMTX only n = 48 n = 45
 Sex (male vs female) Not included 2.59 (1.16-5.81), P = .021
 LDH (elevated vs normal) 1.76 (0.89-3.48), P = .104 Not included
 LMO2 IHC (positive vs negative) Not included 1.33 (0.61-2.92), P = .479
 BCL6 FISH (positive vs negative) 2.62 (1.33-5.17), P = .006 1.12 (0.46-2.71), P = .806

LDH, lactate dehydrogenase.